Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue (2022 - 2025)

Historic Non-Current Deffered Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Q3 2025 value amounting to $31.8 million.

  • Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue rose 16933.37% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 16933.37%. This contributed to the annual value of $31.8 million for FY2024, which is 16611.18% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Non-Current Deffered Revenue of $31.8 million as of Q3 2025, which was up 16933.37% from $31.8 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue peaked at $31.8 million during Q4 2024, and registered a low of $11.8 million during Q2 2024.
  • Its 4-year average for Non-Current Deffered Revenue is $17.4 million, with a median of $12.0 million in 2022.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue plummeted by 1638.26% in 2023 and then soared by 16960.76% in 2025.
  • Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue (Quarter) stood at $12.0 million in 2022, then dropped by 0.38% to $12.0 million in 2023, then soared by 166.11% to $31.8 million in 2024, then changed by 0.0% to $31.8 million in 2025.
  • Its Non-Current Deffered Revenue stands at $31.8 million for Q3 2025, versus $31.8 million for Q2 2025 and $31.8 million for Q1 2025.